Skip to main content

Advertisement

Table 3 Comparison of clinical outcome when data from different regimens of luteal triptorelin were cumulated

From: GnRH agonists to sustain the luteal phase in antagonist IVF cycles: a randomized prospective trial

No Triptorelin<  35 yearsBPPRDRIRAR
87/279 (31,2%)72/279 (25,8%)66/279 (23,6%)17,52%24,1%
Triptorelin<  35 years168/507 (33,1%)153/507 (30,1%)*143/507 (28,2%)*23,45%*14,8%
No Triptorelin≥ 35 years71/241 (29,4%)61/241 (25,3%)54/241 (22,4%)14,12%23,9%
Triptorelin≥ 35 years104/317 (32,8%)93/317 (29,3%)*87/317 (27,4%)*19,78%*16,3%
No TriptorelinTotal patients158/520 (30,3%)133/520 (25,6%)120/520 (23,1%)15,6%24,05%
TriptorelinTotal patients272/824 (33%)246/824 (29,8%)**230/824 (27,9%)**22,15%**15,4%
  1. BP cycles with HCG positive, PR Pregnancy rate (clinical pregnancy), DR Delivery rate, IR Implantation rate, AR Abortion rate (ratio between the pregnancy that did not arrive to delivery and the total HCG positive)
  2. * P < 0,05 compared to the corresponding group with no luteal triptorelin
  3. ** p < 0,01 compared to the corresponding group with no luteal triptorelin